2024 ISPE Annual Meeting

The 2024 ISPE Annual Meeting was held in Berlin, Germany, from August 24 to 28, 2024. More information on the conference can be found here.

A variety of Sentinel-related work was featured, including presentations, posters, and more. 

Symposia

• Advancing Drug Safety Signal Management through Multimodal Approaches in Networking
• Methodological Advances in Regulatory Real World Evidence Generation Systems: Perspectives from Sentinel and DARWIN-EU
• Natural Language Processing in Pharmacoepidemiology: Lessons from the Multi-source Observational Safety Study for Advanced Information Classification using NLP (MOSAIC-NLP)

Oral Presentations

• Assessment of Non-cardiac Congenital Malformations and In Utero Exposure to Modafinil/Armodafinil in the Sentinel Distributed Database
• Comparative Bleeding Risks Among NOAC Users for Nonvalvular Atrial Fibrillation Aged <65 Years in the Sentinel System
• Comparing the Risk of Adverse Infant Outcomes Among Pregnancies with and without COVID-19 in the Sentinel System
• High-Dimensional Multiple Imputation (hdMI) Strategies for Partially Observed Confounders with Structured and Natural Language Processing-Derived Auxiliary Covariates
• Predicting Causes of Death from Structured Electronic Health Records Using Machine Learning
• Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk 

Spotlight Posters

• Pediatric Utilization of New Molecular Entities (NMEs): A Summary of Early Post-Marketing Uptake in the Sentinel Distributed Database
• Tree-Based Mining of Real-World Data for Potential Safety Signals Associated with the Use of Dupilumab in the United States
• Untangling National Medicaid Data: 30 Data Quality Metrics to Support Maternal Health Studies in Two Common Data Models

Posters

• Analysis of Medicinal Product Utilization Data in the FDA Sentinel System to Inform the Development of a Pregnancy Safety Study Framework 
• Analysis of New Molecular Entity Utilization Patterns using the Sentinel Distributed Database
• Assessing Exposure to Recently Approved Medications to Inform Feasibility for Signal Identification Analyses in the FDA’s Sentinel System
• Beta-Blocker-Associated Hypoglycemia in Pediatric Patients: Findings from the FDA Adverse Event Reporting System, National Poison Data System, Medical Literature, and Sentinel Distributed Database 
• Characterization of COVID-19 Vaccine Data in the Sentinel System
• Characterizing Infants in the Sentinel Distributed Database Mother-Infant Linkage Table 
• Characterizing Inpatient Electronic Health Records (EHR) from a Large Hospital Network for Use in Neonatal Pharmacoepidemiology Studies in the United States 
• Characterizing Pediatric Members in the Sentinel Distributed Database: An Update with Data from Medicaid
• Comparative Postmarketing Safety Assessment of Baloxavir Marboxil vs Oseltamivir using TreeScan™
• COVID-19 Related Changes in Healthcare Utilization Among Insured Persons in the US and its Impact on Pharmacoepidemiologic Research 
• Patterns of Prescribing and Dispensing Medicines Among Non-Hospitalized Pregnant Women with COVID-19: A Prospective Meta-Analysis Pooling Findings from Healthcare Databases in Europe and North America
• Prenatal Syphilis in the US: Characterizing Screening and Treatment During Pregnancy in Publicly and Commercially Insured Individuals
• Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework 
• Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium Dependent Glucose Co-Transporter 2 Inhibitors in the FDA Sentinel System